丝裂霉素、长春地辛、顺铂联合治疗Ⅲ～Ⅳ期非小细胞肺癌近期疗效分析  

THERAPEUTIC EFFECT OF COMBINED TREATMENT OF MMC PLUS VDS PLUS CDDP FOR NON-SMALL-CELL LUNG CANCER AT STAGE Ⅲ～Ⅳ

作　　者：朱跃国[1] 潘慧君[1] 

机构地区：[1]上海市北医院肿瘤科,上海市200435

出　　处：《中国煤炭工业医学杂志》2002年第1期55-56,共2页Chinese Journal of Coal Industry Medicine

摘　　要：目的　探讨MVP联合化疗方案治疗Ⅲ～Ⅳ期非小细胞肺癌近期疗效和耐受性。方法　统计分析 1 998年 5月— 2 0 0 0年 5月接受化疗的 31例Ⅲ～Ⅳ期非小细胞肺癌患者。结果　总有效率 38.7% ,主要毒副反应为骨髓抑制和胃肠道反应。结论　MVP方案治疗非小细胞肺癌疗效肯定 ,毒性可耐受 ,可以作为一线治疗方案。Objective To investigate the short-term treatment effect and toxicity of MVP (MMC+VDS+CDDP) for non-small-cell lung cancer (NDCLC). Methods Clinical data from 31 cases of NSCLC at stage Ⅲ～Ⅳ who received chemotherapy were analyzed during May 1998 to May 2000. Results The total response rate was 38.7%, and the major toxic and side effect occurred in tolerable myelo-suppresion and gastrointestinal tract reaction. Conclusion MVP is an effective and safe chemotherapy which can be the first choice for the treatment of NSCLC patients at the stage of Ⅲ and Ⅳ.

关 键 词：非小细胞肺癌 药物联合治疗 丝裂霉素 长春地辛 顺铂 Ⅲ-Ⅳ期 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]